Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, today announced that its DepoVax(TM) adjuvanting
technology will underlie the design of a new cancer vaccine trial that will be
conducted by the Dana-Farber Cancer Institute to treat cervical and head and
neck cancer. 


In a competitive process, Dana-Farber has been awarded a research grant of $1.2
million for clinical evaluation of its cancer vaccine. The grant from Stand Up
To Cancer (SU2C) and the Farrah Fawcett Foundation was awarded to a team of
Dana-Farber researchers in a ceremony last evening at the 2014 American
Association for Cancer Research (AACR) annual meeting. 


The three-year grant will be used to fund a Phase I clinical trial of the
group's peptide cancer antigen formulated in DepoVax in patients with
HPV-related cervical and head and neck cancers.


The grant was awarded based on a proposal highlighting the potential of
Dana-Farber's proposed cancer antigen identified by a new mass spectrometry
method termed Poisson detection MS and Immunovaccine's DepoVax platform. The
DepoVax data focused on clinical trial results with DPX-Survivac, which
demonstrated strong immune response activity in cancer patients and the immune
enhancement observed with the immune modulating agent cyclophosphamide.
Dana-Farber's proposed Phase I study in HPV-related cancers will use the same
approach, formulating the Institute's peptide-based vaccine in DepoVax and
administering it to patients in combination with cyclophosphamide.


"We believe that the grant committee was encouraged by novel interdisciplinary
science in conjunction with the powerful immunogenicity data that Immunovaccine
has collected to date with our DPX-Survivac cancer vaccine candidate," stated
Marc Mansour, Ph.D., chief operating officer of Immunovaccine. "We are excited
to work with the talented team at Dana-Farber and add value to their clinical
program with our DepoVax technology. Our previous work with DPX-Survivac gives
us confidence that DepoVax has the potential to induce strong immunological
responses to their novel antigen to enable the vaccine in the clinic."


The SU2C-Farrah Fawcett Foundation HPV Translational Research Team Grant
provides three years of funding for a multidisciplinary, translational cancer
research project that addresses critical problems in HPV-related cancers and
that can deliver near-term patient benefit through investigation by a team of
two expert investigators. To be considered for the grant, research project
designs were required to include clear plans indicating how the work will be
translated into the clinic and deliver near-term benefits to patients with
HPV-related cancers. HPV infection causes virtually all cervical cancers, and
many anal, vaginal, vulvar, penile, and oropharyngeal cancers. 


About DepoVax(TM)

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in solid tumors and blood cancers including ovarian, breast,
colon and lung cancers, among others. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting
resistance to various anti-cancer therapies. Survivin is also a prognostic
factor for many cancers and it is found in high percentage of cancer patients.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
search for tumor cells expressing survivin and destroy them. 


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Dr. Marc Mansour
Chief Operating Officer
Immunovaccine Inc.
T: (902) 492-1819
E: mmansour@imvaccine.com


Tim Brons
Vida Strategic Partners (media)
T: (415) 675-7402
E: tbrons@vidasp.com